Oculopharyngeal Muscular Dystrophy (OPMD) Market Size

  • Report ID: 5825
  • Published Date: Mar 05, 2024
  • Report Format: PDF, PPT

Oculopharyngeal Muscular Dystrophy (OPMD) Market Size

Oculopharyngeal Muscular Dystrophy Market size is poised to surpass USD 10 Billion by the end of 2036, growing at a CAGR of 14% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of the oculopharyngeal muscular dystrophy was USD 4 Billion. The market growth is on account of the rising prevalence of OPMD among the growing middle-aged population. According to MedlinePlus, muscular disease affects 1-100,000 people, especially occurring in the middle-aged population mostly after the age of 45. Affected patients can usually first experience weakness of the muscles in both eyelids that causes droopy eyelids and develop weakness in throat muscles making it hard for the patient to see or swallow.

Furthermore, other factors that are believed to fuel the growth of the market are advancements in symptomatic treatments like CP myotomy, and gastrostomy feeding tube insertion which are mostly aimed at reducing the symptoms and gaining signs for the comfort and well-being of the patients. This factor provides an additional opportunity for key players present in the market to expand their research and development activities.


Oculopharyngeal Muscular Dystrophy (OPMD) Market
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 5825
  • Published Date: Mar 05, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The oculopharyngeal muscular dystrophy market growth is owing to factors like expanding geriatric population, introduction of new therapies, and increase in healthcare expenditure.

The market size of oculopharyngeal muscular dystrophy market is anticipated to attain a CAGR of 14% over the forecast period, i.e., 2024-2036.

The major players in the market are, Bioblast Pharma, PTC Therapeutics, NS Pharma, Nobelpharma Co., Ltd, Santhera Pharmaceuticals, Pfizer Inc., Marathon Pharmaceuticals, Fibrinogen, GSK and others.

The symptomatic segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample